Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday

Connect Biopharma (NASDAQ:CNTB) is expected to be issuing its H1 2025 results before the market opens on Friday, September 5th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter. Parties are encouraged to explore the company’s upcoming H1 2025 earningoverview page for the latest details on the call scheduled for Wednesday, August 13, 2025 at 9:00 AM ET.

Connect Biopharma Trading Down 1.1%

Shares of Connect Biopharma stock opened at $1.76 on Friday. The business has a fifty day simple moving average of $1.68 and a 200-day simple moving average of $1.10. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.01. Connect Biopharma has a 12 month low of $0.51 and a 12 month high of $2.86.

Institutional Investors Weigh In On Connect Biopharma

An institutional investor recently bought a new position in Connect Biopharma stock. XTX Topco Ltd purchased a new stake in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 28,862 shares of the company’s stock, valued at approximately $29,000. XTX Topco Ltd owned 0.05% of Connect Biopharma as of its most recent SEC filing. 58.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Connect Biopharma in a research report on Wednesday, August 13th. Wall Street Zen upgraded Connect Biopharma to a “hold” rating in a report on Friday, August 22nd. Finally, Northland Capmk upgraded Connect Biopharma to a “strong-buy” rating in a report on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Strong Buy” and a consensus price target of $7.00.

Connect Biopharma Company Profile

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.